The Cost-Effectiveness of Early Access to HIV Services and Starting cART in the UK 1996–2008 by Beck, Eduard J. et al.
The Cost-Effectiveness of Early Access to HIV Services
and Starting cART in the UK 1996–2008
Eduard J. Beck
1,2,11*, Sundhiya Mandalia
1,3,11, Roshni Sangha
1, Peter Sharott
4, Mike Youle
1,5, Guy Baily
6,
Ray Brettle
7, Mark Gompels
8, Margaret Johnson
5, Brendan McCarron
9, Ed Ong
10, Anton Pozniak
11,
Achim Schwenk
12, Stephen Taylor
13, John Walsh
14, Ed Wilkins
15, Ian Williams
16, Brian Gazzard
1,3,11, for
the NPMS-HHC Steering Group
1NPMS-HHC CIC, Coordinating and Analytic Centre, London, United Kingdom, 2London School of Hygiene & Tropical Medicine, London, United Kingdom, 3Imperial
College, London, United Kingdom, 4London Specialised Commissioning Group, London Procurement Programme, London, United Kingdom, 5Royal Free Hospital,
London, United Kingdom, 6Royal London and Barts Hospitals, London, United Kingdom, 7Edinburgh General Hospital, Edinburgh, United Kingdom, 8Southmead
Hospital, Bristol, United Kingdom, 9James Cook University Hospital, Middlesborough, United Kingdom, 10Newcastle General Hospital, Newcastle, United Kingdom,
11Chelsea and Westminster Hospital, London, United Kingdom, 12North Middlesex Hospital, London, United Kingdom, 13Birmingham Heartland Hospital, Birmingham,
United Kingdom, 14St. Mary’s Hospital, London, United Kingdom, 15North Manchester General Hospital, North Manchester, United Kingdom, 16Mortimer Market
Centre, London, United Kingdom
Abstract
Aim: To calculate use, cost and cost-effectiveness of people living with HIV (PLHIV) starting routine treatment and care
before starting combination antiretroviral therapy (cART) and PLHIV starting first-line 2NRTIs+NNRTI or 2NRTIs+PIboosted,
comparing PLHIV with CD4#200 cells/mm3 and CD4.200 cells/mm3. Few studies have calculated the use, cost and cost-
effectiveness of routine treatment and care before starting cART and starting cART above and below CD4 200 cells/mm3.
Methods: Use, costs and cost-effectiveness were calculated for PLHIV in routine pre-cART and starting first-line cART,
comparing CD4#200 cells/mm3 with CD4.200 cells/mm3 (2008 UK prices).
Results: cART naı ¨ve patients CD4#200 cells/mm3 had an annual cost of £6,407 (95%CI £6,382 to £6,425) PPY compared
with £2,758 (95%CI £2,752 to £2,761) PPY for those with CD4.200 cells/mm3; cost per life year gained of pre-cART
treatment and care for those with CD4.200 cells/mm3 was £1,776 (cost-saving to £2,752). Annual cost for starting
2NRTIs+NNRTI or 2NRTIs+PIboosted with CD4#200 cells/mm3 was £12,812 (95%CI £12,685–£12,937) compared with £10,478
(95%CI £10,376–£10,581) for PLHIV with CD4.200 cells/mm3. Cost per additional life-year gained on first-line therapy for
those with CD4.200 cells/mm3 was £4639 (£3,967 to £2,960).
Conclusion: PLHIV starting to use HIV services before CD4#200 cells/mm3 is cost-effective and enables them to be
monitored so they start cART with a CD4.200 cells/mm3, which results in better outcomes and is cost-effective. However,
25% of PLHIV accessing services continue to present with CD4#200 cells/mm3. This highlights the need to investigate the
cost-effectiveness of testing and early treatment programs for key populations in the UK.
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Introduction
Recent studies have demonstrated the cost-effectiveness of starting
combination antiretroviral therapy (cART) at CD4 counts between
201–350 cells/mm3 [1]. Analyses comparing specific treatment
regimens demonstrated improved outcomes and lower costs when
starting cART with higher CD4 counts; a CD4 count of 200 cells/
mm3 remains a watershed cut-off point with those starting ART.200
CD4 cells/mm3 having better outcomes, using fewer services with
lower costs compared with those starting ART#200 cells/mm3 [1].
Most recent studies have focused on comparing different cART
regimens. Few have recently investigated the use of services, their
cost and cost-effectiveness of starting cART above or below a CD4
count of 200 cells/mm3; even fewer studies have estimated the use
and cost of services by people living with HIV (PLHIV) before
starting cART and the cost-effectiveness of this pre-cART
treatment and care. If PLHIV are diagnosed with a CD4.200
and are linked to HIV services and followed up on a regular basis,
this will enable them to start cART at a more optimum CD4
count.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27830The first objective of this study was to estimate the annual use,
cost and cost-effectiveness of service provision for those PLHIV
entering routine HIV treatment and care before starting cART,
comparing those with CD4#200 cells/mm3 with those with a
CD4 count .200 cells/mm3; secondly to estimate the use, cost
and cost-effectiveness of starting first-line with two nucleoside
reverse transcriptase inhibitors with a non-nucleoside reverse
transcriptase inhibitor or boosted protease inhibitor -
2NRTIs+NNRTI or 2NRTIs+PIboosted respectively - with a
CD4#200 cells/mm3 compared with a CD4.200 cells/mm3.
Methods
The National Prospective Monitoring System on the use, cost
and outcome of HIV service provision in UK hospitals - HIV
Health-economics Collaboration (NPMS-HHC) has been moni-
toring prospectively the effectiveness, efficiency, equity and
acceptability of treatment and care in participating HIV units
since 1996. Using an agreed minimum dataset, standardized data
are routinely collected in clinics and transferred to the NPMS-
HHC Coordinating and Analytic Centre (CAC). Since the data
were transferred in pseudo-anonymized format, patient consent
was not required according to the UK Department of Health,
which is in line with international guidelines [2]. While ensuring
patient and clinic confidentiality, the data were analyzed at clinic
and aggregate levels: clinic specific analyses remain confidential,
while aggregate analyses become public documents [3,4].
Use and cost of services
Data on the use of hospital inpatient, outpatient and dayward
services between 1
st January 1996 and 31
st December 2008, were
obtained from computerized information systems from 15 UK
hospitals participating in this analysis. 2NRTIs+NNRTI or
2NRTIs+PIboosted regimens are currently the preferred regimens
for starting first-line cART and have been routinely available in
NPMS-HHC clinics since 1996. Subjects who started these
regimens since 1996 were included in the study while patients
who were transferred from other HIV units were excluded as it
was not possible to establish with certainty whether these regimens
were indeed their first-line regimen.
The mean numbers of inpatient days, outpatient visits and
dayward visits per patient-year (PPY) were calculated for naı ¨ve
patients before they started cART and those who started first-line
2NRTIs+NNRTI or 2NRTIs+PIboosted. A patient-year was
defined as 365.25 days of follow up. The denominator for cART
naı ¨ve patients consisted of the total duration of follow up for all
cART naı ¨ve patients before starting cART, from when they were
first seen until the end of the study period if still alive and cART
naı ¨ve, or the data were censored at the date if they started cART,
were lost to follow up or if they had died.
The denominator for those on first-line 2NRTIs+NNRTI or
2NRTIs+PIboosted consisted of the total duration of follow up
during the period of first-line treatment with 2NRTIs+NNRTI or
2NRTIs+PIboosted, from when they were first seen till the end of
the study period if still alive, or the date if they failed first-line
2NRTIs+NNRTI or 2NRTIs+PIboosted, were lost to follow-up or
died, which ever came first.
First-line 2NRTIs+NNRTI or 2NRTIs+PIboosted failure was
defined as any change made to the regimens, which included
intensification of regimen by adding any anti-retroviral drug to the
regimen or swapping the NNRTI or a PIboosted to another anti-
retroviral drug class. Dropping a NRTI, NNRTI or PIboosted alone
or simplification of anti-retroviral (ARV) combination with no
other changes made to the regimen did not constitute treatment
failure. Causes for failure included clinical, immunological or
virological reasons and others, where adverse effects were the most
likely cause [5].
Numerators for cART naı ¨ve patients were calculated by
summing the use of inpatient, outpatient or dayward services
until first-line cART, while numerators for those on first-line
2NRTIs+NNRTI or 2NRTIs+PIboosted were calculated by sum-
ming the use of inpatient, outpatient or dayward services while on
these first-line regimens. Mean use of services and 95% confidence
intervals (95%CI) PPY were calculated using the Poisson test for
the naı ¨ve population and those who started first-line 2NRTIs+
NNRTI or 2NRTIs+PIboosted disaggregated by CD4 count when
starting routine treatment and care or first-line ART respectively.
The mean use of services PPY was calculated based on a method
for calculating the use of services employed in previous studies
[1,6,7,8] and summarized by the formula:
M~
X n
i~1
X k
j~1
Sij
X n
i~1
X k
j~1
(tij{ti(j{1))
X365
Where n=total number of individuals;
k=day of censoring;
Sij=use of service of individual i at jth day;
tij=number of days starting and remaining cART naı ¨ve or
on first-line 2NRTIs+NNRTI or 2NRTIs+PIboosted by
CD4 stratum for individual i;
M=mean of services S per patient-year by CD4 stratum.
The unit cost for an average inpatient day was £511, £101 for
an outpatient visit and £413 per dayward visit [9]. Inpatient,
outpatient and dayward costs PPY were obtained by multiplying
their means and 95%CIs PPY by their respective unit costs for
PLHIV starting at different CD4 counts. For naı ¨ve patients the
costs generated by the use of services for each of the CD4
categories were added to the costs of ‘other’ drugs, tests and
procedures performed; for those on first-line 2NRTIs+NNRTI or
2NRTIs+PIboosted, the use of services costs were added to the cost
of ARVs, ‘other’ drugs and tests and procedures performed [9].
The costs for the different 2NRTIs+NNRTI or 2NRTIs+PIboosted
regimens were the weighted average annual prices based on prices
negotiated by the London HIV Consortium in 2008 with
pharmaceutical companies. Furthermore, the costs for ‘other
drugs’ and test and procedures were weighted by stage of HIV
infection: asymptomatic, symptomatic non-AIDS or AIDS. The
study was performed from a public service perspective [10] and
costs for use of services, ‘other’ drugs, tests and procedures
performed, were obtained from the 2010 NPMS-HHC report [9].
Costs were calculated in UK pounds (2008 prices) and time-to-
starting cART, time to first-line failure of 2NRTIs+NNRTI or
2NRTIs+PIboosted regimens and treatment costs were discounted
at 3.0% per annum [11].
CD4 counts when starting pre-cART routine treatment
and care and cART
Baseline CD4 counts were obtained within 4 months before or
after of starting routine treatment and care for cART naı ¨ve
patients and for those starting first-line 2NRTIs+NNRTI or
2NRTIs+PIboosted. In a minority of cases CD4 counts could not be
obtained and for these patients their baseline CD4 count was
imputed. For the cART naı ¨ve patients a total of 690 (2%) CD4
counts were imputed; for those starting 2NRTIs+NNRTI or
Early Access to HIV Services and Starting cART
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imputed.
CD4 counts were imputed using the Multiple Imputations (MI)
procedure in SAS assuming that the data were multivariate
normally distributed and that the missing CD4 count data were
missing at random (MAR). The missing CD4 counts were
substituted with an estimated value using a multiple imputation
procedure which replaced each missing value with a set of
plausible values that represented the uncertainty about the right
value to impute [12]. The Markov chain Monte Carlo (MCMC)
statement was used to predict mean matching method for
imputation, a method that assumed multivariate normality [13].
The MCMC method imputed an observed value that was nearest
to the predicted value from the simulated regression model for
each missing value imputed.
Regression Models, Time-to-starting cART and Time-to-
Treatment Failure
Parametric quantitative data are presented as means with 95%
confidence intervals (95%CIs) or standard deviation (SD) while
non-parametric data are presented as medians with inter-quartile
range (IQR). Between group comparisons of parametric data with
more than two independent groups were tested using one-way-
ANOVA while two independent groups were compared using
unpaired t-test. Between group comparisons of non-parametric
data with three independent groups were tested using the Kruskal-
Wallis test while two independent groups were compared using the
Mann-Whitney U test. Qualitative data by CD4 count strata were
tested using the x
2 test and where appropriate these were adjusted
using Yates’ correction.
Median and inter-quartile ranges were used to create categories,
including a separate category for all variables with missing data.
This ensured no degrees of freedom were lost when building
multivariable models. Cox’s proportional hazards regression
models with single variables were initially used to estimate
likelihood of treatment failure. All variables found to have a
probability of p,0.2 in univariate Cox’s proportional hazards
model were used to build a multivariable model to assess the risk of
a particular prognostic variable while controlling for the other
variables in the model.
The final multivariable models of the CD4 strata presented
were tested for their distributional assumptions using Cox Snell
residual plots and adjusted for sex, age, baseline viral load,
baseline CD4 count, stage of HIV infection, other variables in the
models and stratified by year of starting pre-cART routine
treatment and care or first line 2NRTIs+NNRTI or 2NRTIs+-
PIboosted for possible confounding or residual effects. Baseline viral
load and CD4 cell count were defined as those available 4 months
before or after starting pre-cART routine treatment and care or
starting first-line 2NRTIs+NNRTI or 2NRTIs+PIboosted; baseline
clinical stage was based on the diagnosis within 30 days since
starting pre-cART routine treatment and care or 2NRTIs+
NNRTI or 2NRTIs+PIboosted. Event time was defined as time-
to-starting cART or time-to-treatment failure of first-line ART
based on patient days of follow up. These were estimated from the
start of the study period of 1
st January 1996, or the date of entry
into the cohort if entry to the cohort came after this date, to either
the end of the study period of 31
st December 2008 or starting
cART, failure of 2NRTIs+NNRTI or 2NRTIs+PIboosted regimens,
or the last recorded visit during their follow-up.
Survival Function Estimation
After adjusting for confounding and residual variables in the
final model, the PROC PHREG in SAS was run with the
BASELINE statement to create a new data set with the ‘‘survival’’
function estimates at the event times of each stratum for each list of
Figure 1. Proportion of cART naı ¨ve PLHIV diagnosed and entered routine treatment and care with CD4#200 cells/mm3, CD4.200
cells/mm3 and missing CD4 count, 1996–2008.
doi:10.1371/journal.pone.0027830.g001
Early Access to HIV Services and Starting cART
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e27830variables in the final multivariable model [14]. This contained the
‘‘survival’’ function estimates corresponding to the means of the
variables in the model for each stratum. The resulting survival
function estimates were used to model with event time as a
covariate based on the least squares maximum likelihood model.
The resulting least squares regression model was then used to
estimate the extrapolated median and inter quartile ranges (IQR)
of time-to-starting cART or first-line treatment failure. All analyses
were performed using SAS version 9.1.3 statistical software and all
significance tests presented are two-tailed.
Life year gained for cART naı ¨ve patients and those on
first-line cART
Based on differences in the estimated starting or failure times,
the additional life years gained in routine treatment and care of
pre-cART or on first-line 2NTRIs+NNRTI or 2NRTIs+PIboosted
regimens by CD4 stratum were calculated based on methods used
for previous analyses [1,6,7,8]. The incremental cost-effectiveness
ratios (ICERs) were calculated using time-to-starting cART or
time-to first-line 2NRTIs+NNRTI or 2NRTIs+PIboosted failure
respectively as the outcome measures of the two analyses and were
calculated using the following formula [10]:
ICER~½Costs A{Costs B =½Outcome A{Outcome B 
A cost-effectiveness analysis and scenario analyses were produced
for the cART naı ¨ve population and those that started first-line
2NTRIs+NNRTI or 2NRTIs+PIboosted. The lower bound of the
scenatio analyses consisted of the lower 95% confidence interval of
the annual cost combined with the lower quartile of time-to-
starting cART or time-to-first line failure of 2NTRIs+NNRTI or
2NRTIs+PIboosted regimens respectively; the upper bound consist-
ed of the upper 95% confidence interval of the annual cost
combined with upper quartile of time-to-starting ART or time-to-
first line failure of 2NTRIs+NNRTI or 2NRTIs+PIboosted
regimens respectively.
Table 1. Demographic characteristics, mean (95%CI) use of services and associated annual costs for cART naı ¨ve people living with
HIV by CD4 strata.
CD4#200
N=8155 (27%)
CD4.200
N=20496 (67%)
CD4 Missing
N=1907 (6%) p-value
Sex ,0.001
Female 2267 (27.8) 3994 (19.5) 406 (21.3)
Male 5888 (72.2) 16502 (80.5) 1501 (78.7)
Mean Age (SD) 35.7 (10.5) 32.6 (9.1) 33.5 (9.7) ,0.001
Ethnic group ,0.001
Unknown 1606 (19.7) 2926 (14.3) 475 (24.9)
Other 1325 (16.2) 3274 (16.0) 261 (13.7)
Black African 1896 (23.2) 2641 (12.9) 334 (17.5)
Caucasian 3328 (40.8) 11655 (56.9) 837 (43.9)
IDU ,0.001
Yes 396 (4.9) 926 (4.5) 183 (9.6)
No 7759 (95.1) 19570 (95.5) 1724 (90.4)
Geometric mean CD4 count (95%CI) cells/mm3 64 (62–65) 439 (436–441) Not applicable ,0.001
Clinic location Not applicable ,0.001
London 6,054 (26.6) 16,692 (73.4)
Non-London 2,101 (35.6) 3,804 (64.4)
CD4#200 CD4.200
Mean Inpatient
Days (95% CI) 2.76 (2.74–2.78) 0.41 (0.40–0.42)
Costs £1411 (£1398–£1422) £207 (£205–£208)
Mean Outpatient
Visits (95% CI) 8.32 (8.25–8.34) 6.22 (6.21–6.23)
Costs £840 (£832–£842) £628 (£627–£629)
Mean Dayward
Visits (95% CI) 0.77 (0.76–0.78) 0.41 (0.40–0.42)
Costs £318 (£312–£323) £168 (£166–£170)
Average use of services costs – subtotal (95% CI) £2,569 (£2,544–£2,587) £1,004 (£998–£1,007)
Other drug cost £3,070 £1,293
Tests + procedures £768 £461
Total annual cost (95% CI) £6,407 (£6,382–£6,425) £2,758 (£2,752–£2,761)
doi:10.1371/journal.pone.0027830.t001
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cART naı ¨ve patients
A total of 30,558 naı ¨ve patients were seen during the study
period in participating clinics. Of these 8,155 (27%) had a
CD4#200 cells/mm3 when first starting pre-cART routine
treatment and care, 20,496 (67%) had a CD4 count .200 cells/
mm3 and 1,907 (6%) did not have a CD4 recorded nor could this
be imputed. The proportion of PLHIV who were first diagnosed
with a CD4#200 cells/mm3 remained remarkably constant
during the study period at around 25% (Figure 1). Patients
presenting with a CD4#200 cells/mm3 were more likely to be
older, women or black Africans, and attend a non-London clinic
compared with those presenting with a CD4 count .200 cells/
mm3. Mean baseline CD4 count for the former group was 64
cells/mm3 (95% CI 62–65) compared with 439 cells/mm3
(95%CI 436–441) for the latter (Table 1).
Use of inpatient, outpatient and dayward services were
significantly higher in those patients with CD4#200 cells/mm3
resulting in higher costs annual costs of services of £2,569 (95%CI
£2,544 to £2,587) compared with £1,004 (95% CI £998 to £1,007)
for cART naı ¨ve patients presenting with CD4 count .200 cells/
mm3. ‘Other’ drug cost and costs for tests and procedures were
also higher for the naı ¨ve patients who presented with CD4#200
cells/mm3, resulting in a substantially higher total annual cost of
£6,407 PPY (95%CI £6,382 to £6,425) for these patients
compared with £2,758 PPY (95%CI £2,752 to £2,761) for PLHIV
with CD4.200 cells/mm3 (Table 1).
Estimated time to starting ART was 0.7 years (IQR 0 to 5.6) for
those presenting with a CD4#200 cells/mm3 compared with 5.3
years (IQR 1.0 to 9.8) for those presenting with CD4.200 cells/
mm3 (Table 2). This resulted in a cost of £1,776 per life year
gained of routine treatment and care pre-cART, with a lower
bound of £2,752 and an upper bound which was cost-saving
(2£3,615) per additional life-year gained in pre-cART treatment
and care (Table 3).
Patients starting antiretroviral therapy
During the study period, 5,858 patients started on
2NTRIs+NNRTI or 2NRTIs+PIboosted regimens. Of these,
2,134 (36%) started with a CD4#200 cells/mm3, and the
remaining 3,724 (64%) started with CD4.200 cells/mm3. Again,
these proportions remained relatively stable during the study
period (Figure 2). Most of the demographic characteristics of those
Table 2. Multivariable Cox’s proportional hazards regression model showing significant independent predictors of the likelihood
of starting first-line cART.
*Hazard Ratio 95% CI Score statistics p-value
Age at HIV diagnosis Missing 1.12 (1.06–1.18) ,0.001
#27.2 0.95 (0.90–1.00) 0.044
27.3–32.5 0.99 (0.94–1.04) 0.579
32.6–38.5 1.00 (0.95–1.05) 0.886
.38.5 1
Sex Female 1.23 (1.19–1.28) ,0.001
Male 1
First ever viral load (missing imputed) Missing 1.15 (0.90–1.48) 0.269
.144000 1.57 (1.50–1.65) ,0.001
29201–144000 1.40 (1.33–1.46) ,0.001
3601–29200 1.01 (0.96–1.06) 0.682
#3600 1
First Diagnosis AIDS 1.42 (1.37–1.48) ,0.001
Non AIDS 1
First ever CD4 Missing 0.15 (0.11–0.20) ,0.001
.200 0.53 (0.51–0.55) ,0.001
#200 1
*Adjusted for sex, baseline VL, Baseline AIDS, and stratified by year of starting pre-cART routine treatment and care and other variables in the model.
doi:10.1371/journal.pone.0027830.t002
Table 3. Estimated time-to-starting first-line cART and cost-effectiveness of starting pre-cART routine treatment and care,
comparing PLHIV starting with CD4.200 cells/mm3 and CD4#200 cells/mm3 (lower and upper bounds).
PLHIV starting pre-cART routine treatment and care
#200 CD4 cells/mm3 .200 CD4 cells/mm3
Estimated median (IQR) days to starting cART 242 (0 to 2028) 1941 (355 to 3527)
Cost – effectiveness of additional year gained as naı ¨ve patient (lower – upper bound) £1776 [£2752 to cost-saving (2£3615)]
doi:10.1371/journal.pone.0027830.t003
Early Access to HIV Services and Starting cART
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(Table 4). PLHIV starting cART with CD4#200 cells/mm3 were
older, more likely to be women or black African, however they
were also more likely to have an history of injecting drugs; no
differences were observed whether they were being managed in
clinics in- or outside of London. The mean CD4 count differed
significantly between the groups and was 83 cells/mm3 (95% CI
79–86) compared with 350 cells/mm3 (95%CI 346–354).
Use of inpatient, outpatient and dayward services was
significantly greater in those who started with a CD4#200 cells/
mm3 and this was reflected in higher annual costs of £2,806
(95%CI £2,755–£2,856) compared with £1,763 (95% CI £1,733–
£1,794) for those starting cART with CD4.200 cells/mm3. Cost
of first-line cART was similar for both groups, while the group
starting cART with lower CD4 counts had higher ‘other’ drug
costs and costs for tests and procedures (Table 4). The total annual
cost for the group starting with CD4#200 cells/mm3 was £12,812
PPY (95%CI £12,685–£12,937), which was significantly higher
compared with the group starting with CD4.200 cells/mm3
which had an annual cost of £10,478 PPY (95%CI £10,376–
£10,581; Table 4).
The estimated time to first-line treatment failure was 14.7 years
(IQR 6.8 to 22.7) for those starting with a CD4.200 cells/mm3
compared with 10.4 years (IQR 4.8–16.0) for those who started
with a CD4#200 cells/mm3 (Table 5). The average cost per
additional life-year gained on first-line therapy for those starting
cART with CD4.200 cells/mm3 was £4639, with a lower bound
of £3,967 and upper bound of £2,960 per additional life year
gained on first-line cART (Table 6).
Discussion
For PLHIV to be diagnosed early after they have been infected
and have access to HIV services is to ensure that they can be
monitored over time and start cART at an optimum CD4 count,
when the immunological damage inflicted by HIV infection is less
extensive and response to cART is optimal. Given that the
additional costs per life-year gained are well below the £35,000
cut-off point, at which NICE considers interventions not to be
cost-effective [15], providing access to HIV services for PLHIV
with a CD4 count .200 cells/mm3 and monitoring them before
they start cART is very cost-effective. It enables the immunolog-
ical status of PLHIV to be monitored over time to ensure that
these PLHIV start cART with CD4 counts above 200 cells/mm3.
Also remarkable was the considerable reduction in annual cost
for both cART groups compared with earlier analyses [1]. This
was due to a reduction in use of services but also a reduction in the
ARV costs, which decreased over time, and points to the
effectiveness of these regimens. These are some of the efficiencies
which health services need to achieve to make service provision
sustainable, especially during times of a global economic
downturn. It does raise the question whether more community
services are being used by these PLHIV and if so which services,
provided by whom and their cost, cost-effectiveness and
acceptability.
Current BHIVA and WHO guidelines advocate that PLHIV
should start cART when CD4 count drops below 350 cells/mm3
[16,17]; other guidelines now suggest that cART can be started
when CD4 counts drops below 500 cells/mm3 [18], while some
practitioners have now started prescribing cART as soon as an
individual has been diagnosed with HIV infection, irrespective of
CD4 count [19]. While the START trial - due to end in 2015 - will
provide answers to these questions [20], most practitioners agree
that cART should be started well before CD4 counts drop below
200 cells/mm3.
Given the recent results of the HPTN 052 trial [21], the benefits
for starting cART not only include increased survival and reduced
morbidity of those PLHIV on cART, but the demonstrated
Figure 2. Proportion of PLHIV starting 2NTRIs+NNRTI or 2NRTIs+PIboosted with CD4#200 cells/mm3 and CD4.200 cells/mm3, 1996–
2008.
doi:10.1371/journal.pone.0027830.g002
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line 2NTRIs+NNRTI or 2NRTIs+PIboosted by CD4 strata.
CD4#200
N=2134 (%)
CD4.200
N=3724 (%) p-value
Sex ,0.001
Female 578 (27.1) 816 (21.9)
Male 1556 (72.9) 2908 (78.1)
Mean Age (SD) 38.0 (9.3) 36.8 (9.4) ,0.001
Ethnic group ,0.001
Unknown 311 (14.6) 386 (10.4)
Other 354 (16.6) 537 (14.4)
Black African 498 (23.3) 637 (17.1)
Caucasian 971 (45.5) 2164 (58.1)
IDU 0.016
Yes 109 (5.1) 141 (3.8)
No 2025 (94.9) 3583 (96.2)
Geometric mean CD4 count (95%CI) cells/mm3 83 (79–86) 350 (346–354) p,0.001
Clinic location p=0.112
London 1,519 (35.8) 2,722 (64.2)
Non-London 615 (38.0) 1,002 (62.0)
CD4#200 CD4.200
Mean Inpatient
Days (95% CI) 2.94 (2.89–2.99) 1.38 (1.35–1.41)
Costs £1501 (£1474–£1529) £705 (£691–£719)
Mean Outpatient
Visits (95% CI) 7.88 (7.78–7.96) 7.12 (7.05–7.20)
Costs £795 (£786–£804) £719 (£712–£727)
Mean Dayward
Visits (95% CI) 1.23 (1.20–1.27) 0.82 (0.80–0.84)
Costs £510 (£495–£523) £339 (£330–£348)
Average use of services costs – subtotal (95% CI) £2,806 (£2,755–£2,856) £1,763 (£1,733–£1,794)
Average annual cART costs (95% CI) £5,998 (£5,923–£6,074) £6,166 (£6,094–£6,238)
Other drug cost £3,214 £1,971
Tests + procedures £793 £578
Total Annual cost (95% CI) £12,812 (£12,685–£12,937) £10,478 (£10,376–£10,581)
doi:10.1371/journal.pone.0027830.t004
Table 5. Multivariable Cox’s proportional hazards regression model showing significant independent predictors of the likelihood
of treatment failure for first-line 2NTRIs+NNRTI or 2NRTIs+PIboosted.
*Hazard Ratio 95% CI Wald statistics p-value
Age at start of therapy #31.3 1.47 (1.18–1.84) ,0.001
31.4–36.5 1.60 (1.30–1.98) ,0.001
36.6–42.3 1.52 (1.22–1.88) ,0.001
.42.3 1
Baseline CD4 range (missing imputed) #200 1.23 (1.06–1.43) 0.007
.200 1
ART at start of 1
st line HAART 2NA+PIboosted 1.12 (0.93–1.36) 0.227
2NA+NNRTI 1
*Adjusted for sex, baseline VL, Baseline AIDS, and stratified by year of starting first-line 2NTRIs+NNRTI or 2NRTIs+PIboosted and other variables in the model.
doi:10.1371/journal.pone.0027830.t005
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HIV transmission at individual and population levels. As was
recently pointed out, any successful response to the UK HIV
epidemic will need to include a reduction in HIV transmission
through more effective HIV prevention measures, which are likely
to require behavioural, biomedical and structural interventions
[22].
Despite the large number of subjects followed-up over the years,
the analyses as presented have their limitations. Firstly, the data
were collected in 15 sites, including both London and out-of
London clinics, but 79% of patients contributing to this study,
were seen in London clinics. Secondly first CD4 count when
starting routine treatment and care pre-cART or starting
2NTRIs+NNRTI or 2NRTIs+PIboosted could not be retrieved
for a small number of subjects and these had to have their CD4
count imputed. Thirdly, sub-analyses were not performed for
specific groups of PLHIVs, like men who have sex with men
(MSM) or specific ethnic groups and different populations may be
diagnosed with different CD4 counts. Fourthly, the data available
for operational research are by definition observational data [23].
While adjustments were made for some key potential confounders,
some residual confounding may have remained and affected the
results.
It remains disconcerting, that a quarter of PLHIV when first
diagnosed and enrolled in these clinics for pre-cART services had
a CD4#200 cells/mm3, a proportion which remained constant
during the study period. Recent studies performed in the UK
highlighted the fact that different populations have been diagnosed
with different CD4 counts. For instance, between 1993 and 2002,
the percentage of MSM diagnosed with HIV and a CD4 count
,200 cells/mm3 in England and Wales decreased from 38% to
25% [24]. For newly diagnosed heterosexual PLHIVs in England
and Wales between 2000 and 2004, 42% had a CD4,200 cells/
mm3 [25]. In the latter study, 74% of the heterosexual sample
were black-Africans and only 11% Caucasian heterosexuals; 43%
of black-African heterosexual individuals were diagnosed with a
CD4 count ,200 cells/mm3, compared with 36% of black-
Caribbean or white heterosexual individuals respectively. Of the
black-African heterosexuals infected in the UK, 20% were
diagnosed with a CD4 count ,200 cells/mm3 compared with
44% of heterosexuals infected in Africa [25].
As was recently reported [26], significant proportions of
PLHIVs across Europe continue to present late and the authors
of the study concluded that the ‘‘evidence points to high rates of
late diagnosis across Europe – between 15% and 38% of all HIV
cases – and concur that trends are increasing or at best stagnant’’
[26].
The implications for those presenting with CD4 counts #200
cells/mm3 is that once they start cART their estimated time-to-
first-line treatment failure is significantly shorter that those who
start with a CD4 count .200 cells/mm3, while the costs of
services before and after starting cART are higher. In fact, of the
estimated 83,000 individuals living with HIV in the UK in 2008 –
which increased to an estimated 86,500 in 2009 - 26% were
thought to be unaware of being infected and did not know their
sero-status [27].
Whether it is cost-effective to institute testing and early
treatment programs in the UK, either for key or general
populations as was recently proposed in the US [28] remains to
be assessed. However, as the US study reiterated, while early
treatment can play an important part in containing a country’s
HIV epidemic, it is likely that only through combined behavioural,
biomedical and structural interventions that the greatest impact
can be achieved.
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